WYSE, PHD, J. J.; MORASCO, PHD, B. J.; DOBSCHA, MD, S. K.; DEMIDENKO, BS, M. I.; MEATH, MPH, T. H. A.; LOVEJOY, PHD, MPH, T. I. Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified. Journal of Opioid Management, [S. l.], v. 14, n. 4, p. 295–303, 2018. DOI: 10.5055/jom.2018.0461. Disponível em: https://wmpllc.org/ojs/index.php/jom/article/view/1798. Acesso em: 28 apr. 2024.